NCT06901505 - To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis | Biotech Hunter

Enrollment

350

Participants

Timeline

Start Date

July 24, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Anemia of Chronic Kidney Disease

Interventions

DRUG

Erythropoiesis-Stimulating Agent (ESA)

Administered by intra-venous (IV) infusion.

DRUG

Vadadustat

300mg, oral tablets

Trial Locations (18)

36117-7306

RECRUITING

DaVita Research Site, Montgomery

06112-1260

RECRUITING

DaVita Research Site, Hartford

06705-3893

RECRUITING

DaVita Research Site, Middlebury

31904-3604

RECRUITING

DaVita Research Site, Columbus

55435-1807

RECRUITING

DaVita Research Site #1, Minneapolis

RECRUITING

DaVita Research Site, Minneapolis

89052-5548

RECRUITING

DaVita Research Site, Henderson

89128-0804

RECRUITING

DaVita Research Site, Las Vegas

79835-2200

RECRUITING

DaVita Research Site #1, El Paso

RECRUITING

DaVita Research Site, El Paso

77054-3836

RECRUITING

DaVita Research Site #1, Houston

RECRUITING

DaVita Research Site, Houston

78258-4800

RECRUITING

DaVita Research Site #1, San Antonio

RECRUITING

DaVita Research Site #2, San Antonio

RECRUITING

DaVita Research Site, San Antonio

77384-3024

RECRUITING

DaVita Research Site, The Woodlands

23502-3235

RECRUITING

DaVita Research Site #1, Norfolk

RECRUITING

DaVita Research Site, Norfolk